Skip to content

Trial Summary

This is a safety, efficacy, and pharmacokinetics (PK) study of MK-7684 as monotherapy and in combination with pembrolizumab (MK-3475) or pembrolizumab plus pemetrexed and carboplatin in adults with metastatic solid tumors for which there is no available treatment.

Acronym:

MK7684

ACTRN/NCT /ethics:

NCT02964013

Scientific title:

A Phase I trial of MK-7684 as monotherapy and in combination with pembrolizumab in subjects with advanced solid tumours.

Sponsor / Cooperative group:

Merck

Trial & Patient Characteristics

Cancer TypeAll cancers
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
SexBoth
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2016-12-13
Anticipated End Date2024-01-15

Participating Hospitals

HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Emailsyeend@adelaidecancercentre.com.au
Phone08 8292 2240
Principal InvestigatorDr Brian Stein
Recruitment StatusRecruiting